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Introduction
Traditional chemotherapy agents were the mainstay of 
therapy for patients with chronic lymphoid leukemia (CLL) 
and mantle cell lymphoma for many years. Recently, the 
approval of several new agents with targeted mechanisms of 
action has resulted in a paradigm shift in the treatment of 
these diseases. However after the relatively rapid approval 
of new drugs, the full toxicity profile may not be apparent 
until a broader population of patients is exposed in the post 
marketing setting. 
Ibrutinib is a Bruton tyrosine kinase inhibitor (1,2) that 
is approved for the treatment of mantle cell lymphoma after 
at least one prior therapy (3), chronic lymphocytic leukemia 
with or without a 17p deletion (4-6) and Waldenstrom’s 
macroglobulinemia (7). The most common toxicities 
reported are cytopenias, diarrhea, fatigue, infection, 
musculoskeletal pain and bruising. Bleeding events occurred 
in all of the trials but were grade 1 or 2 in most patients. 
In the mantle cell lymphoma trial, bleeding occurred in 
48% of patients (3), with 5% of patients having grade 3 
or higher bleeding events including subdural hematoma, 
gastrointestinal bleeding, or hematuria. In the phase II CLL 
trial bruising was reported in 54% of patients (4), and was 
grade 3/4 in 2% of cases. In the phase III CLL trial, four 
patients treated with ibrutinib had grade 3 hemorrhage and 
one had grade 4 hemorrhage (5).
We recently treated two patients who developed life 
threatening central nervous system (CNS) bleeding while 
on ibrutinib. Both patients had a platelet count that was 
above that which would be expected to result in spontaneous 
bleeding. Both patients had cessation of bleeding after 
administration of platelet transfusions.
Case presentation
Patient 1 
The patient is a 66 years old woman who was diagnosed 
with CLL in 2005 after routine blood work demonstrated 
lymphocytosis. In 2012 she received 4 cycles of fludarabine, 
cytoxan, rituxan (FCR) for the treatment of progressive 
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lymphocytosis and lymphadenopathy. She was again well 
until February 2015 when she developed progressive 
lymphocytosis, lymphadenopathy and splenomegaly. The 
patient was treated with ibrutinib 420 mg orally daily. 
She was not taking any other medications. She tolerated 
therapy well until November 2015 when she awoke 
suddenly with intractable vomiting and confusion. The 
patient was transported to a local hospital where, upon 
arrival, she was unresponsive with a Glasgow coma score 
of 8. She was intubated for airway protection and sedated. 
A CT scan showed acute intraventricular hemorrhage with 
subarachnoid blood. The patient was transferred to our 
hospital for further therapy. 
Upon arrival at our hospital there were no extraocular 
movements and the pupils were 2 mm. The patient 
localized to noxious stimuli. Sedation was held for 
neurological evaluation. There was no lymphadenopathy 
or hepatosplenomegaly palpable. Laboratories showed 
a white blood count (WBC) of 165,000/mm3 with 6% 
neutrophils, 85% lymphocytes, 1% monocytes, and 8% 
atypical lymphocytes. The hemoglobin was 13.8 g/dL, and 
the platelet count was 137,000/mm3. Peripheral blood flow 
cytometry confirmed the diagnosis of CLL with 87% of 
cells co-expressing CD5, CD19, CD20, CD22, and CD23 
(heterogeneous). Fluorescence in situ hybridization (FISH) 
subsequently demonstrated abnormalities of 6q- and 13q-. 
The IGH gene variable region was unmutated. Results of 
platelet aggregation studies and other coagulation tests 
which were performed are summarized in Table 1. The only 
abnormality detected was a mild decrease in reaction to 
collagen (59%) on platelet aggregation studies. 
A non-contrast CT scan of the head demonstrated 
extensive intraventricular hemorrhage within the occipital 
horns of the lateral ventricles, third ventricle, and 
fourth ventricle. There was also a small amount of acute 
subarachnoid hemorrhage within the sylvian fissures. There 
was hydrocephalus with dilation of the ventricular system 
and there was partial effacement of the cerebral hemispheric 
sulci. A CT angiogram of the head and neck demonstrated 
no evidence of intracranial aneurysm nor arteriovenous 
malformation. An MRI demonstrated extensive gradient 
hypointensity within the ventricular system consistent with 
Table 1 Laboratory results
Test Normal range Patient 1 Patient 2
White blood count (/mm3) 4,800–10,800 165,000 500
Hemoglobin (g/dL) 14.0–18.0 13.8 9.9 
Platelet count (/mm3) 160,000–410,000 137,000 99,000
Prothrombin time (s) 9.8–12.0 10.4 10.8
Partial thromboplastin time (s) 25.0–32.0 23.7 30.5
Fibrinogen (mg/dL) 180–400 359 317
Factor VIII (%) 50–100 109 —
Ristocetin cofactor (%) 50–100 89 —
Von Willebrand multimers Normal Normal —
Factor XIII Normal Normal Normal
Platelet aggregation collagen (%) 66.00–98.00 59 —
Platelet aggregation ADP (%) 61.00–97.00 66 —
Platelet aggregation epinephrine (%) 61.00–93.00 65 —
Platelet aggregation ristocetin (%) 72.00–104.00 73 —
PAI-1 antigen (ng/mL) 3–72 17 —
Euglobulin lysis (s) >60 >60 >60
Factor Xa (%) 70–150 87 75
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acute intraventricular hemorrhage, as well as MRI findings 
consistent with subarachnoid hemorrhage. Additionally 
there was moderate atrophy and moderate chronic small 
vessel ischemic changes. 
A ventriculostomy was placed. The patient was given 
single donor platelet transfusions every 6 h for a total 
of 8 transfusions. The patient improved rapidly and was 
discharged to a rehabilitation unit 11 days after admission. 
At the time of discharge the patient was awake and alert and 
fully ambulatory. She had residual deficits in the extraocular 
muscle movements of the right eye and a mildly altered 
affect at the time of transfer. At a 3 months follow-up visit 
her modified Rankin score was 0, she had no deficits and 
her speech was normal.
Patient 2 
The patient was an 80-year-old man with history of 
chronic obstructive pulmonary disease, atrial fibrillation on 
warfarin, glaucoma, and basal cell carcinoma. He initially 
presented in January 2012 with cervical lymphadenopathy. 
A fine needle aspiration performed at an outside institution 
showed small lymphocytic leukemia. Initially a watch and 
wait approach was chosen. In July of 2015 the patient 
presented with progressive lymphadenopathy and a chest 
wall mass. Core biopsy of the mass demonstrated a diffuse 
lymphoid infiltrate. The lymphocytes were medium to large 
in size with fine chromatin. Immunohistochemistry showed 
that the cells were positive for CD20, PAX-5, CD5, BCL-1, 
SOX-11, BCL-2, and negative for MUM-1, CD23, BCL-
6, CD10. The Ki67 was 90% and FISH demonstrated the 
CCND1/IGH rearrangement. The findings were consistent 
with blastoid variant mantle cell lymphoma.
Due to the patient’s age and comorbities he received a 
less intensive regimen than is typical for this disease. He 
received 3 cycles of bendamustine and rituxan. Although 
he initially demonstrated a significant reduction in the size 
of the mass and lymph nodes, he had clinical progression 
after the third cycle of therapy. Concurrently the patient 
developed a right third cranial nerve palsy. Lumbar 
puncture confirmed lymphomatous meningitis. 
The patient was transferred to our care.  After 
discontinuation of his anticoagulation an Ommaya catheter 
was placed. He received intrathecal methotrexate and was 
discharged to receive treatment closer to home. The patient 
was treated with ASA 81 mg daily rather than warfarin for 
his high risk cardiac disease. Two weeks later the patient 
began ibrutinib 420 mg orally daily concurrently with 
intrathecal methotrexate given on a weekly schedule. Three 
weeks later the patient returned with severe fatigue. On 
physical exam the patient was lethargic and febrile. The 
complete blood count showed a WBC of 500/mm3 with 
88% neutrophils and 12% lymphocytes. The hemoglobin 
was 9.9 g/dL and the platelet count was 99,000/mm3. The 
LDH was 1,392 U/L, the creatinine was 1.63 mg/dL and 
the uric acid was 22.3 units. Coagulation studies were 
unremarkable and are listed in Table 1. 
CT scan  o f  the  bra in  demons t ra ted  b i l a te ra l 
holohemispheric subdural collections up to 1 cm in maximal 
thickness, which was hyperdense compared to CSF. The 
left-sided collection had a higher density component 
compatible with acute on subacute subdural hemorrhage. 
The right-sided collection was favored to represent a 
subacute subdural hemorrhage. There was no shift of 
midline structures or hydrocephalus.
The patient was treated with intravenous antibiotics, 
filgrastim, steroids and rasburicase. Single donor platelets 
were given every 6 h for a total of 17 transfusions. A follow 
up CT showed the expected evolution of blood products but 
no further bleeding. The patient subsequently developed 
pneumonia and respiratory failure and, after palliative 
therapy was initiated, he expired.
Discussion
Ibrutinib is a targeted agent that is highly active against 
a range of B-cell malignancies. Although bleeding events 
were noted in the clinical trials, few details of the patients’ 
coagulation status, treatment and outcome were reported. 
In vitro studies have recently demonstrated that platelet 
aggregation abnormalities occur after exposure to ibrutinib. 
Rigg reported that irreversible inhibition of BTK with two 
ibrutinib analogs significantly decreased glycoprotein VI-
mediated platelet activation, spreading, and aggregation 
in vitro (8). Likewise, Bye demonstrated that platelets 
treated with ibrutinib adhered to collagen under arterial 
shear but formed unstable thrombi and that integrin 
αIIbβ3 outside-in signaling was also effected in addition 
to glycoprotein VI signaling (9). The authors concluded 
that ibrutinib causes glycoprotein VI and integrin αIIbβ3 
platelet signaling deficiencies that result in formation of 
unstable thrombi and that combining ibrutinib with P2Y12 
antagonists may have a detrimental effect on hemostasis.
Lipsky et al. prospectively assessed platelet function 
and coagulation factors in 85 patients treated on a trial of 
ibrutinib for chronic lymphocytic leukemia (10). After a 
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median follow-up of 24 months the authors recorded grade 
1 or 2 bleeding events in 55% of the patients. No grade 3/4 
events occurred. The median time to bleeding was 49 days 
and the risk of an event plateaued by 6 months. In this trial, 
von Willebrand factor and factor VIII levels were often high 
at baseline and then normalized on treatment. Collagen 
and adenosine diphosphate induced platelet aggregation 
was decreased in all patients with chronic lymphocytic 
leukemia, whether on ibrutinib or not. Compared to 
untreated chronic lymphocytic leukemia patients, response 
to collagen showed a mild further decrement on ibrutinib, 
while response to adenosine diphosphate improved. The 
authors concluded that both disease and treatment-related 
factors influenced the risk of bleeding. In a smaller clinical 
study, Levade et al. demonstrated that ibrutinib selectively 
inhibited platelet signaling and functions downstream of the 
collagen receptor glycoprotein VI and strongly affected firm 
platelet adhesion on von Willebrand factor under arterial 
flow (11). The addition of 50% untreated platelets was 
sufficient to efficiently reverse the effects of ibrutinib, and 
platelet functions recovered after treatment interruption 
as physiological platelet renewal occurred. Kamel et al. 
also noted that 23 patients receiving ibrutinib all had 
reductions in collagen-mediated platelet aggregation, and 
that there was a significant association between the degree 
of inhibition and the occurrence of clinical bleeding or 
bruising (12). 
Our first patient had no major risk factors for CNS 
bleeding and developed life threatening hemorrhage 
without any warning. The only abnormality found was a 
very mild reduction in platelet aggregation in response 
to collagen. Our second patient multiple risk factors for 
hemorrhage. He had a recent neurosurgical procedure as 
well as lymphomatous meningitis. He also had a history of 
atrial fibrillation and was on low dose aspirin at the time of 
his hemorrhage. Due to the reports of platelet dysfunction 
we treated both of our patients with platelet transfusions, 
even though one had a normal platelet count and the other 
had only a mild reduction in platelet count. The first patient 
had a dramatic improvement in her clinical condition 
after the infusions. The second patient had resolution of 
bleeding, but opted for comfort care after he developed 
pneumonia and he subsequently expired from causes 
unrelated to the hemorrhage. 
It is impossible to know if the resolution of bleeding was 
directly related to the platelet transfusions administered or 
was just due to clearance of ibrutinib and production of new 
platelets by the patient. However, in view of the favorable 
bleeding outcomes, we propose that this is a reasonable 
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